LLY · News · 20260922N
Regulatory Approval Milestones
ELI LILLY & Co · 2026-09-22 · Importance 38 · Surprise 60 · In source text
The FDA granted full approval to Eli Lilly’s Inluriyo (imlunestrant) for use with Verzenio (abemaciclib) in pretreated patients with ESR1-mutated breast cancer. The decision converts the treatment’s prior regulatory status to full approval and expands Lilly’s oncology product positioning. The approved use targets a biomarker-defined breast-cancer population that has received previous treatment.
Key facts
- The U.S. Food and Drug Administration granted full approval to Eli Lilly's Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for pretreated breast cancer patients. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | The U.S. Food and Drug Administration granted full approval to Eli Lilly's Inluriyo (imlunestrant) in combination with Verzenio… |